Researchers analysed thousands of laboratory-made plasmids and discovered that nearly half of them had defects, raising questions of experimental reproducibility.
Aggregated News
According to comments from Kathy Hudson, NIH deputy director for science, and Carlos Peña, director of emerging technology programs at FDA's Office of the Commissioner, leaders from the two government bodies will be putting their heads together to help FDA bring its regulations up to speed with technological and scientific advancements.
"We have created a joint leadership program with FDA and the expectation is that we would be able to provide them with some of our scientific expertise, be able to help them streamline some of their processes," Hudson said this week at the Personalized Medicine World Conference in Mountain View, Calif.
In June, NIH Director Francis Collins and FDA Commissioner Margaret Hamburg co-wrote an article in the New England Journal of Medicine in which they discussed their "shared vision of personalized medicine and the scientific and regulatory structure needed to support its growth.
"Together, we have been...